On 11 August, Curaleaf announced its intention to launch a take-over bid for Aurora Cannabis at US$4.00 per share. For the European sector, the price is not the point — the asset is. Curaleaf is after more than 50 tonnes of annual EU-GMP certified cultivation and manufacturing capacity. Europe has become the prize, and certified capacity the bottleneck.
What is on the table
The proposal combines 0.3463 Curaleaf shares and US$0.75 in cash per Aurora share, a 45% premium over Aurora’s 30-day volume-weighted average price (US$2.75), with a cap price of US$5.00. The combined company would post more than US$1.5 billion in trailing twelve-month revenue, adjusted EBITDA of around US$350 million, and a footprint across 17 countries including Germany, the UK, Poland, Australia and New Zealand. Curaleaf expects at least US$40 million in annual cost synergies.
The industrial logic is explicit. Curaleaf International already runs three EU-GMP facilities — in Portugal, Spain and Canada — focused on processing and distribution; Aurora would bring the cultivation. “We approached Aurora privately and constructively on multiple occasions,” said Boris Jordan, Curaleaf’s CEO, justifying the unsolicited route after the board declined to engage. Aurora replied that the proposal lacked detail, without ruling out further dialogue. Full terms are in Curaleaf’s announcement.
August, the month of EU-GMP audits
This is not an isolated move. On 4 August, SNDL announced it had passed the EU-GMP audit at its Atholville facility in New Brunswick and expects certification within 90 days. Ten days later, Canopy Growth renewed the EU-GMP certification of its Kincardine facility in Ontario, granted by the Regierungspräsidium Tübingen in Baden-Württemberg. CEO Luc Mongeau put the goal plainly: supplying high-quality EU GMP flower directly from Canada. The company also operates a second certified facility in Sankt Leon-Rot, Germany.
Three moves in eleven days, all pointing at the same certificate. EU-GMP has stopped being an administrative requirement and become the metric that sets valuations across the sector.
Europe is now the main market
The numbers explain the urgency. In its fiscal first quarter of 2027, reported on 5 August, Aurora posted net revenue of C$67.6 million, up 12% year on year. International medical cannabis grew 17% to C$43 million, driven by Germany, and 64% of total revenue now comes from outside Canada, up from 50% a year earlier. Adjusted gross margin held at 58%, though adjusted EBITDA fell to C$3.4 million from C$10.8 million. The expansion of its Leuna facility in Germany will double flower output. Canopy, meanwhile, lifted international net revenue 10% year on year.
The pattern repeats: North American domestic markets are flat while Europe absorbs certified production faster than installed capacity can supply it.
What it means for business
- EU-GMP is now bought, not just applied for. When a certification is valued in the hundreds of millions, acquiring a certified facility competes directly with building one.
- Fewer, larger suppliers. Supply-side concentration shifts bargaining power over contracts, pricing and lead times for distributors, pharmacies and laboratories.
- Germany and Poland set the pace. They absorb the volume today and are where the distribution models that will reach the rest of the EU are being tested.
- Spain is on the production map. Even with a domestic market still limited to hospital-dispensed magistral formulas, the country already hosts export-oriented EU-GMP capacity.
- Timelines gate market entry. Audit to certification takes 90 days or more; anyone who has not started the process will struggle to be operational in 2027.
From deal-making to the negotiating table
A consolidation phase redefines who you sign with, at what price and to which quality standard. For Spanish and European companies — producers, laboratories, distributors and investors — the immediate task is identifying which partners will still be standing after the reshuffle, and meeting them before the contracts are closed.
That is precisely the conversation Spannabis B2B Bilbao 2027 is built around. The International Cannabis Business Forum takes place on 11 March 2027 at the BEC VIP Room in Bilbao. Check the tickets or book your B2B table to schedule meetings with producers, distributors and investors from across the sector.